期刊文献+

抗乳腺癌多形上皮黏蛋白1单克隆抗体的制备及初步应用 被引量:1

Preparation and preliminary application of anti-human breast cancer MUC1 monoclonal antibody
原文传递
导出
摘要 目的 制备并鉴定抗多形上皮黏蛋白1(MUC1)单克隆抗体,将抗体应用于人乳腺癌组织、纤维腺瘤、囊性增生症及正常乳腺组织的临床鉴别,采用免疫组化方法进行检测.方法 用合成的MUC1重复序列短肽与钥孔血蓝蛋白(KLH)及牛血清白蛋白(BSA)偶联后作为抗原免疫Balb/c小鼠,杂交瘤技术筛选出稳定分泌单克隆抗体的细胞株.制备单克隆抗体,以ELISA、Western blot、流式细胞术、免疫荧光法对抗体进行特异性鉴定及亚类分析;将抗体应用于人乳腺癌组织、纤维腺瘤、囊性增生症及正常乳腺组织的临床鉴别,采用免疫组化方法进行检测.结果 获得4株稳定分泌抗MUC1的杂交瘤细胞株,第1株反应性最强,效价1∶10 7以上.抗体亚型3株为IgG1,1株为IgM,轻链均为κ型.经Western blot、流式细胞术、免疫荧光、免疫组化检测证实抗体与乳腺癌细胞株MCF-7特异性结合,单抗检测MUC1在乳腺癌组织与纤维腺瘤、囊性增生症及正常乳腺组织之间表达差异明显(均P<0.01).结论 抗MUC1单克隆抗体经检测效价高、特异性强,为乳腺癌早期诊断和靶向治疗的进一步研究奠定了基础. Objective To prepare the anti-human MUC1 monoclonal antibody (mAb) and to apply it in human breast cancer tissues,fibro adenoma,cystic hyperplasia and normal breast tissues,using immunohistochemistry assay.Methods Synthetic MUC1 repetitive sequence short peptide coupled with KLH protein and BSA protein as antigen to immunize Balb/c mice,cell lines capable of secreting monoclonal antibodies were screened by hybridoma cell fusion technique.The specificities and subclasses of the prepared monoclonal antibodies were identified and analyzed by ELISA,Western blot,flow cytometry and immunofluorescence test.The antibodies were used in the detection of clinical human breast cancer,benign fibro adenoma and normal breast tissue by immunohistochemical methods.Results Four hibridoma cell lines secreting specific anti-MUC1 mAbs were obtained,The titers of the most powerful antibody were above 1 ∶ 107.3 strains were of IgG1 antibody,one was of IgM,and the light chain of which was categorized into chain to.The mAb could specifically bind to the MCF-7 cells,which was verified by Western blot,flow cytometry analysis,fluorescence immunoassay and immunohistochemistry test.Significant differences of expression (all P < 0.01) of the detection of MUC1 monoclonal antibodies were found in breast cancer tissue,fibro adenoma,cystic hyperplasia and normal breast tissues.Conclusions The mAb against MUC1 developed in this study is of high titers and specific for breast cancer,exhibiting a favourable prospect for early diagnosis and targeted therapy of breast cancer.
出处 《中华普通外科杂志》 CSCD 北大核心 2015年第6期480-484,共5页 Chinese Journal of General Surgery
基金 国家自然科学基金资助项目(81072180)
关键词 乳腺肿瘤 黏蛋白类 抗体 单克隆 Breast neoplasms Mucins Antibody,monoclonal
  • 相关文献

参考文献9

  • 1Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013 [ J]. CA Cancer J Clin, 2013, 63( 1 ) : 11-30.
  • 2郑莹,吴春晓,张敏璐.乳腺癌在中国的流行状况和疾病特征[J].中国癌症杂志,2013,23(8):561-569. 被引量:852
  • 3Yuan S, Shi C, Liu L, et al. MUCl-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy [ J ]. Expert Opin Biol Ther, 2010, 10 ( 7 ) : 1037-1048.
  • 4Lin S X, Chen J, Mazumdar M, et al. Molecular therapy of breast cancer: progress and future directions [ J ]. Nat Rev Endocrinol, 2010, 6(9): 485-493.
  • 5Ghosh S K, Pantazopoulos P, Medarova Z, et al. Expression of underglycosylated MUC1 antigen in cancerous and adjacent normal breast tissues [ J ]. Clin Breast Cancer, 2013, 13 (2) : 109-118.
  • 6Nath S, Mukherjee P. MUC1 : a multifaceted oncoprotein with a key role in cancer progression[J]. Trends Mol Med, 2014, 20 (6) : 332-342.
  • 7Buss N A P S, Henderson S J, McFarlane M, et al. Monoclonal antibody therapeutics: history and future [ J ]. Curr Opin Pharmacol, 2012, 12(5) : 615-622.
  • 8Salouti M, Babaei M H, Rajabi H, et al. Evaluation of breast tumor targeting with radiolabeled F (ab') 2 fragmant of a new anti-MUC1 monoclonal antibody ( PR81 ) [ C ]//World Congress on Medical Physics and Biomedical Engineering, 2009, Munich, Germany. Springer Berlin Heidelberg, 2009: 143-144.
  • 9马忠良,李振甫,张虹,王占民.抗乳腺癌单克隆抗体的制备及其应用[J].四川肿瘤防治,2001,14(2):69-71. 被引量:1

二级参考文献34

  • 1王启俊,祝伟星,邢秀梅.北京城区女性乳腺癌发病死亡和生存情况20年监测分析[J].中华肿瘤杂志,2006,28(3):208-210. 被引量:81
  • 2陈建国,朱健,张永辉.启东市1972~2000年主要恶性肿瘤生存率分析[J].中国肿瘤,2006,15(9):575-578. 被引量:34
  • 3[1]Coggin JH Jr, Barsoum AL, Rohrer JW. Tumors express both unique TSTA and cross protective 44 kDa oncofetal antigen[J ]. Immunol Today, 1998, 19(9) :405-408.
  • 4[2]Sambrook J,Fritsch J,Maniatis T, et al. Molecular cloning;A laboratory manual [J ]. Cold Sping Harbor Laboratory Press. USA, 1989,576.
  • 5[3]White CA, Dulbecco R, Allen R, et al .Two monoclonal antibodies selective for human mammary carcinoma[J] .Cancer Res, 1985, 45:1337.
  • 6[4]Choicher D, Hand PH, Nuti M, et al. A spectrum of monoclonal antibodies reactive with human mammary tumor cells[J] .Proc Natl Acad Sci USA, 1981,78: 3199.
  • 7全国肿瘤防治研究办公室 卫生部卫生统计信息中心.中国试点市、县恶性肿瘤的发病与死亡(1993-1997)[M].北京:中国医药科技出版社,2002..
  • 8赵平,陈万青,孔灵芝.中国癌症发病与死亡2003-2007[M].北京:军事医学科学出版社,2012:79-90.
  • 9国家癌症中心,卫生部疾病预防控制局.2012中国肿瘤登记年报[M].北京:军事医学科学出版社,2012.30.
  • 10FERLAY J, SHIN H R, BRAY F, et al. GLOBOCAN 2008 vl.2, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010 [ EB/OL ] . http:// globocan.iarc.fr, accessed on 10/05/2013.

共引文献851

同被引文献29

  • 1OECD - organisation for Economic Co-operation and Development(2000). OECD Guidence Document on the Recognition, Assessment and use of Clinical signs as Humane Endpoints for Experimental Animals used in Safety Evaluation.
  • 2Canadian Council on Animal Care. Guidlineson: choosing an appropriate endpoint in experiments using animals for research, teaching and testing. 1998.
  • 3Guide for the care and use of laboratory animals. Eighth Edition. The national academies press. 2010.
  • 4Johannes S, Hartinger J, Hendriksen C F, et al. Humane endpoints in the efficacy testing of swine erysipelas vaccines [ J ]. ALTEX ,2003,20 ( 1 ) : 11 - 15.
  • 5Morton D B. Humane endp0ints in animal experiments for biomedical research [ C ]. Netherlands: Proceedings of the International Conference, 1999:5 - 12.
  • 6Bryan H, Timo N; Gemma P. The Cost Manual of Laboratory Animal Care and Use [ M]. USA:CRC Press,2011:333 -353.
  • 7Ashall V, Millar K. Endpnint matrix: a conceptual tool to promote consideration of the multiple dimensions of humane endpoints[ J]. ALTEX ,2014,31 (2) :209 - 213.
  • 8Morton D B. A systematic Approach for Establishing Humane Endpoints [ J]. ILAR Jour,2000,41 (2) :80 - 86.
  • 9Pain and distress in laboratory rodents and lagomorphs. Report of the Federation of European Laboratory Animal Science Associations (FELASA) Working Group on Pain and Distress accepted by the FELASA Board of Management November 1992 [J]. Lab Anita,1994,28(2):97-112.
  • 10Morton D B, Griffiths P H. Guidelines on the recognition of pain, distress and discomfort in experimental animals and an hypothesis for assessment [ J ]. Vet Rec, 1985, llfi ( 16 ) : 431 -436.

引证文献1

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部